Key result
Left ventricular hypertrophy in hypertension is a common complication modified by cardiovascular risk factors, comorbidities, and the renin-angiotensin-aldosterone system.
Answers are grounded in this paper and cite their sources.
This review highlights the evolving epidemiology and pathophysiology of left ventricular hypertrophy in hypertensive patients, emphasizing the role of comorbidities and molecular mechanisms.
INTRODUCTION: Left ventricular hypertrophy (LVH) is a common complication to hypertension, indicating the presence of hypertensive heart disease, which puts the patient at a very high risk for subsequent clinical cardiovascular events like sudden cardiac death, stroke, myocardial infarction and heart failure. AREAS COVERED: The epidemiology of LVH has changed in recent years as a consequence of the development of new diagnostic tools and demographic changes in hypertensive populations. Expert commentary: In individual hypertensive patients, the presence and type of LVH and associated systolic and diastolic myocardial dysfunction is modified by the co-presence of other cardiovascular risk factors and comorbidities and as well as activation of the reninangiotensin-aldosterone system and other molecular mechanisms involved in LVH pathophysiology. The purpose of this review is to give a clinical update on LVH in hypertension.
No takes yet. Share an insight, caveat, or question.
Cramariuc et al. (2016) conducted a review in Left ventricular hypertrophy in hypertension. Left ventricular hypertrophy in hypertension is a common complication modified by cardiovascular risk factors, comorbidities, and the renin-angiotensin-aldosterone system.
Synapse has enriched 10 related papers. Consider them for comparative context: